<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Cancer</journal-id><journal-id journal-id-type="publisher-id">jca</journal-id><journal-title-group><journal-title>Journal of Cancer</journal-title></journal-title-group><issn pub-type="epub">1837-9664</issn><publisher><publisher-name>Ivyspring International Publisher</publisher-name><publisher-loc>Sydney</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786033</article-id><article-id pub-id-type="doi">10.7150/jca.101911</article-id><article-id pub-id-type="publisher-id">jcav16p1281</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Exploring breast cancer associated-gene panel for next-generation sequencing and identifying new, pathogenic variants in breast cancer from western China</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Cheng</surname><given-names>Jingliang</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Binghui</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Wei</surname><given-names>Chunli</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Lianmei</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="FNA_number" ref-type="author-notes">#</xref></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Xiaoyan</given-names></name><xref rid="A1" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Lisha</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Tima</surname><given-names>Singkome</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Chiampanichayakul</surname><given-names>Sawitree</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Xiao</surname><given-names>Xiuli</given-names></name><xref rid="A5" ref-type="aff">5</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib><contrib contrib-type="author"><name><surname>Anuchapreeda</surname><given-names>Songyot</given-names></name><xref rid="A2" ref-type="aff">2</xref><xref rid="A4" ref-type="aff">4</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Junjiang</given-names></name><xref rid="A1" ref-type="aff">1</xref><xref rid="FNA_envelop" ref-type="corresp">&#x02709;</xref></contrib></contrib-group><aff id="A1"><label>1</label>Key Laboratory of Epigenetics and Oncology, The Research Center for Preclinical Medicine, Southwest Medical University, Luzhou 646000, Sichuan Province, China.</aff><aff id="A2"><label>2</label>Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.</aff><aff id="A3"><label>3</label>Department of Pathology, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an 223300, Jiangsu Province, China.</aff><aff id="A4"><label>4</label>Research Center of Pharmaceutical Nanotechnology, Chiang Mai University, Chiang Mai, 50200, Thailand.</aff><aff id="A5"><label>5</label>Department of Pathology, the Affiliated Hospital, Southwest Medical University, Luzhou 646000, Sichuan Province, China.</aff><author-notes><corresp id="FNA_envelop">&#x02709; Corresponding authors: Dr. Junjiang Fu, Key Laboratory of Epigenetics and Oncology, the Research Center for Preclinical Medicine, Southwest Medical University, Luzhou, Sichuan 646000, P R China. Tel/Fax: +86-830-3160283; E-mail: <email>fujunjiang@swmu.edu.cn</email>. Dr. Songyot Anuchapreeda, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand. E-mail: <email>songyot.anuch@cmu.ac.th</email>. Dr. Xiuli Xiao, E-mail: <email>xiaoxiuli@swmu.edu.cn</email>.</corresp><fn fn-type="equal" id="FNA_number"><p># Equal contributions.</p></fn><fn fn-type="COI-statement"><p>Competing Interests: The authors have declared that no competing interest exists.</p></fn></author-notes><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>13</day><month>1</month><year>2025</year></pub-date><volume>16</volume><issue>4</issue><fpage>1281</fpage><lpage>1295</lpage><history><date date-type="received"><day>5</day><month>8</month><year>2024</year></date><date date-type="accepted"><day>13</day><month>12</month><year>2024</year></date></history><permissions><copyright-statement>&#x000a9; The author(s)</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>). See <ext-link ext-link-type="uri" xlink:href="https://ivyspring.com/terms">https://ivyspring.com/terms</ext-link> for full terms and conditions.</license-p></license></permissions><abstract><p>Breast cancer (BC) is the most frequently diagnosed and the leading cause of cancer-related deaths among women worldwide. It is crucial to develop a cost-effective BC genetic panel for detection and diagnosis. In this study, tissue samples from 52 BC patients and peripheral blood samples from 18 healthy volunteers were collected in western China, followed by gDNA extraction. H&#x00026;E and IHC analysis were employed to detect the expression of invasive BC tissues. We analyzed data using public databases such as COSMIC/ClinVar/HGMD along with our own previously published data and queried commercial BC panels to select high-risk genes. Using Illumina DesignStudio, gene panel primers consisting of 13 genes were designed with 696 primer pairs. The specificity of all primers was validated through common PCR assays. Once the gene panel was completed, multiple polymerase chain reactions (MPCR) were performed using the designed panel primers. The resulting MPCR products were purified to enrich them as library templates. Subsequently, after passing quality tests for library integrity assessment, Next-generation sequencing (NGS) was conducted. Through bioinformatics analysis of the NGS data, 4,571 variants were identified in the annotation files from 52 samples, classified into different types. Among these variants, 358 (approximately 7.8%) were newly discovered and distributed across 11 genes in 52 patients without in the ExAC database. The <italic>KMT2C</italic> gene exhibited the highest frequency of variants, presenting in 83.0% of 52 patient samples. Variants in <italic>BRCA2</italic> (71%), <italic>BRCA1</italic> (48%), <italic>PALB2</italic> (40%), <italic>PIK3CA</italic> (23%), and <italic>RNF40</italic> (21%) genes were found in over 20% of patients. Additionally, variants were observed in the <italic>AKT1</italic> (12%), <italic>ERBB2</italic> (10%), <italic>ESR1</italic> (8%), <italic>TWIST1</italic> (8%), and <italic>PIK3R1</italic> (4%) genes. Further analysis using PolyPhen-2, SIFT, CADD, and Mutation Taster tools analysis showed that out of these new variants, 49 (49/358) had potential pathogenic effects on protein functions and structure across 52 patients. Consequently, a high-risk gene panel has been preliminarily established for early detection/diagnosis that will contribute to earlier prevention and treatment strategies for individuals with BC, particularly those residing in developing or underdeveloped countries. The identification of novel pathogenic variants within our cohort not only expands knowledge regarding genetic diagnosis applications for BC patients but also facilitates genetic counseling services for affected individuals and their families.</p></abstract><kwd-group><kwd>breast cancer</kwd><kwd>gene panel</kwd><kwd>next-generation sequencing (NGS)</kwd><kwd>pathogenic variants</kwd><kwd>gene diagnosis</kwd><kwd>genetic counseling</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="Section1"><title>1. Introduction</title><p>Cancer is a prevailing global healthy issue, particularly in developing or undeveloped countries or regions. According to the GLOBOCAN 2022 data <xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>, breast cancer (BC) has been reported as the second most frequently diagnosed and the fourth leading cause of death among all cancers worldwide. Especially, BC is the most common cancer and the main cause of cancer death among women worldwide. In China, there were approximately 357,200 new cases of BC reported in females in 2022 <xref rid="B3" ref-type="bibr">3</xref>, accounting for 15.47% of new female cases globally with around 75,000 deaths. The increasing incidence and mortality rates of BC patients have made this disease a significant threat to the health of Chinese women. Advancements in clinical diagnosis and treatment have significantly improved BC survival rates, however, there remains a gap between the five-year survival rate of BC patients in China (82.0%) and that observed in developed countries like the United States (90.9%) <xref rid="B4" ref-type="bibr">4</xref>-<xref rid="B6" ref-type="bibr">6</xref>. The discrepancy can be attributed to delayed diagnoses among many BC patients who are already at intermediate or advanced stages with tumor metastasis upon initial detection. Consequently, surgical interventions may occur too late resulting in high post-operative recurrence rates and shorter survival times. To address the challenge posed by rapidly increasing incidence and mortality rates among BC patients, early detection/diagnosis, prevention strategies, and timely treatment must be prioritized <xref rid="B5" ref-type="bibr">5</xref>.</p><p>Precision medicine is an effective approach based on scientific understanding of individual differences arising from genome variation, environment, and lifestyle. It involves precise genetic diagnosis to achieve personalized therapy, and early prevention <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>. In developed Western countries, databases such as ClinVar, the Catalogue of Somatic Mutations in Cancer (COSMIC), next-generation sequencing (NGS) technology, and bioinformatics analysis, are utilized for genetic diagnosis in BC patients. Commercial gene panels have already been developed to cater to their needs <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>. However, in China-a developing country with certain underdeveloped regions like western China-factors such as living habits, educational level, and medical conditions (particularly scientific and technological advancements), contribute to a large number of BC patients being diagnosed at advanced stages with poor prognosis <xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B9" ref-type="bibr">9</xref>-<xref rid="B11" ref-type="bibr">11</xref>. BC has become a prevalent malignant tumor significantly impacting the physical and mental health of women while posing a threat to their lives. The primary cause of death among BC patients lies not in the growth of primary tumors but rather in metastasis and recurrence. Therefore, it is imperative to develop a cost-effective gene panel that can effectively facilitate early prevention, detection, and diagnosis.</p><p>The etiology and pathogenesis of BC are multifactorial and complex, with genetic factors playing an influential role in approximately 5%-10% of cases, while the majority of cases (90%-95%) are sporadic and caused by somatic mutations. Somatic mutations are not inherited, and the primary method employed in this study involved in collecting cancer tissue for comparison with normal tissue or blood samples. The COSMIC database serves a comprehensive resource for exploring the impacts of somatic mutations on different cancers. Notably, <italic>BRCA1</italic> and <italic>BRCA2</italic> genes are the most common disease genes associated with hereditary BC due to their high-frequency germline mutation. Currently, variant interpretation guidelines provided by the American College of Medical Genetics and Genomics/Association for Molecular Pathology (ACMG/AMP) solely focus on germline variants. However, advancements in DNA sequencing techniques such as NGS have facilitated the identification of other BC susceptibility genes including various variants of <italic>TP53</italic>, <italic>PIK3CA</italic>, <italic>PALB2</italic>, and <italic>PTEN</italic> genes. Furthermore, rare genes have been reported to increase the risk of developing metastatic BC <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B12" ref-type="bibr">12</xref>-<xref rid="B14" ref-type="bibr">14</xref>. This study aims to establish a high-risk gene panel for the diagnosis BC in western China to enhance knowledge and information pertaining to the clinical application of genetic diagnosis among BC patients. These findings can provide valuable insights for genetic counseling related to both BC patients and their family pedigrees.</p></sec><sec sec-type="methods" id="Section2"><title>2. Materials and Methods</title><sec id="Section2.1"><title>2.1 Sample collection and DNA extraction</title><p>This study was approved in advance by the Ethics Committee of Southwest Medical University and was conducted in accordance with the principles outlined in the Declaration of Helsinki (2013 version). Tissue samples were recruited from 52 patients with BC, along with blood samples from 18 healthy donors from different families. The patient was diagnosed with BC through pathological examination, and the BC tissue of the patients collected through clinical surgery. Normal people have no disease after clinical examination, and blood samples of normal people are collected through clinical physical examination. Clinical examination and family information, including age, sex, tumor sizes, tumor stage, tumor metastasis, pathological diagnosis, and family history were recorded for BC patients. The expression of Her-2/ER/PR patient pathological samples was utilized for BC pathology reporting across various subtypes. Tumor size and metastasis served as grading systems to determine patient status. Subsequently, DNA extraction was performed using a standard phenol/chloroform method <xref rid="B15" ref-type="bibr">15</xref> on both BC tissues and normal blood samples obtained from patients and healthy donors, respectively. The workflow of this study is illustrated in Figure <xref rid="F1" ref-type="fig">1</xref>A.</p></sec><sec id="Section2.2"><title>2.2 Hematoxylin-Eosin staining and immunohistochemistry</title><p>Patients with BC tissues were fixed in 10% formalin for one day, embedded in paraffin, and sliced every 5 &#x000b5;m. After dewaxing in xylene and dehydrating, the slides were stained with hematoxylin and eosin (H&#x00026;E) before being probed by immunohistochemistry (IHC). The H&#x00026;E and IHC methods were performed as previously described protocols <xref rid="B16" ref-type="bibr">16</xref>-<xref rid="B18" ref-type="bibr">18</xref>. The BRCA1 (cat #: ZM-0347) and TP53 (cat #: ZM-0408) antibodies for IHC were purchased from Beijing Zhong Shan-Golden Bridge Biological Technology Co., Ltd., CN. Slides with a thickness of 5 &#x000b5;m underwent antigen retrieval through incubation in 10 &#x000b5;M sodium citrate buffer at 95&#x000b0;C for three times, 12 min each. Samples were then blocked using a solution containing 5% BSA before primary antibodies for BRCA1 and TP53 (diluted at a ratio of 1:100) were applied overnight. Appropriate biotin-conjugated secondary antibodies (cat #: SP-9000, ZSGB-Bio, CN) were used to incubate the samples at room temperature for an hour before visualization was achieved via streptavidin-conjugated horseradish peroxidase (HRP) and 3,3-diaminobenzidine (DAB) (cat #: ZLI-9017, ZSGB-Bio, CN). Finally, the stained slides underwent retaining with hematoxylin prior to dehydration, mounting, and analysis.</p></sec><sec id="Section2.3"><title>2.3 Design gene panel</title><p>To design the gene panel, we initially conducted an analysis using public databases such as COSMIC/ClinVar/HGMD. Specifically, a comprehensive analysis of the COSMIC database was performed as previously described <xref rid="B19" ref-type="bibr">19</xref>. Subsequently, the top twenty genes were identified with a mutation frequency in BC and searched for specific inhibitors to target these genes through literature research <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B20" ref-type="bibr">20</xref>-<xref rid="B32" ref-type="bibr">32</xref>. Additionally, considering our previous studies and current investigation on BC genes to select high-risk genes specific to the Chinese population in our region <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B35" ref-type="bibr">35</xref>, they were included in the gene panel. Furthermore, to tailor our panel specifically for Chinese individuals at high risk of BC development, commercially available BC panels were compared from Western developed countries <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B36" ref-type="bibr">36</xref>-<xref rid="B38" ref-type="bibr">38</xref>. Thirteen genes (<italic>AKT1, BRCA1</italic>, <italic>BRCA2</italic>, <italic>ESR1</italic>, <italic>ERBB2</italic>, <italic>KMT2C</italic>, <italic>PALB2</italic>, <italic>PIK3CA</italic>, <italic>PIK3R1</italic>, <italic>PTEN</italic>, <italic>TP53</italic>, <italic>RNF40</italic>, and <italic>TWIST1</italic>) were selected for primer design to cover all exons and intron junction sequences. The Illumina DesignStudio was employed to design the primers and set their parameters. The primer set underwent multiple assay steps (AmpliSeq for Illumina Gene) to ensure accuracy before displaying all gene primer information on a webpage table that could be downloaded. Consequently, thirteen genes with corresponding primers pairs totaling up to 696 were synthesized into our designed gene panel. Then, the specificity of primers was assessed by PCR. Finally, the successfully implementation of NGS resulted in the completion of our designed gene panel. The workflow illustrating the process is depicted in Figure <xref rid="F1" ref-type="fig">1</xref>A &#x00026;B.</p></sec><sec id="Section2.4"><title>2.4 Multiple-PCR and product purified analysis</title><p>The multiple-PCR (MPCR) amplification was conducted using genomic DNA (gDNA) as a template in a total volume of 50 &#x000b5;L on a Veriti&#x02122; 96-Well Thermal Cycler. The Multiplex PCR Plus Kit for MPCR purchased from QIAGEN, Germany (cat #: 206152) <xref rid="B39" ref-type="bibr">39</xref> was employed. The components for MPCR were as follows: 25 &#x000b5;L of 2&#x000d7; Multiplex PCR Master Mix*, 5 &#x000b5;L of 10&#x000d7; primer mix, &#x02264;300 ng of template DNA, and RNase-free water to reach a final volume of 50 &#x000b5;L. The cycling protocol for multiplex PCR consisted of an initial denaturation at 95 &#x000ba;C for 5 min, followed by 35 cycles at 95 &#x000ba;C for 30 s, then annealing at 60 &#x000ba;C for 90 s, extension at 72 &#x000ba;C for 30 s, and final extension at 68 &#x000ba;C for 10 min. The amplified MPCR products were purified using AMPure XP Beads (Vazyme Biotech Co., Ltd., N411-01).</p></sec><sec id="Section2.5"><title>2.5 Construction of gene panel library and NGS analysis</title><p>After the successful design of the gene panel, multiplex PCR (MPCR) was performed to amplify our designed panel primers as the library template. The QIAseq 1-Step Amplicon Library kit (QIAGEN, Germany, Cat #: 180412) was utilized for library construction. Subsequently, each sample library was uniquely identified using different adapter sequences. To assess the quality of the libraries, Agilent Fragment Analyzer Systems (Agilent, USA) were employed for library quality control analysis. Each captured sample achieved a depth exceeding 200 &#x000d7; with over 90% coverage. The raw average data size for each sample amounted to 0.7GB, while the sequencing reads exhibited a quality score value around 20, and a base recognition rate surpassing 99%.</p><p>NGS was conducted on the Illumina MiSeq platform (Illumina, USA). For bioinformatics analysis of the NGS data, original reads were converted in FASTQ format and aligned to hg19 using BWA aligner version 0.5.9 <xref rid="B40" ref-type="bibr">40</xref>. Recalibration and local realignment were performed using Genome Analysis Toolkit (GATK version 1.0.5974) <xref rid="B41" ref-type="bibr">41</xref>, followed by variant calling with Atlas2 toolkit <xref rid="B9" ref-type="bibr">9</xref>. Common polymorphisms with an allele frequency higher than 0.5% were filtered based on several common variant databases. Variant annotation was carried out using ANNOVAR <xref rid="B42" ref-type="bibr">42</xref> with RefSeq genes as a reference for coordinate mutations. The variant allele frequency of the variants was calculated from sequencing data. Functional predictions of variants were made using SIFT and PolyPhen-2 tools <xref rid="B43" ref-type="bibr">43</xref>. Known pathogenic mutations were searched in various databases such as COSMIC/ClinVar/HGMD/dbsnp/ExAC <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B44" ref-type="bibr">44</xref>-<xref rid="B46" ref-type="bibr">46</xref>. We identified somatic mutations by adding blood samples of healthy individuals to exclude the germline mutations. Loci associated with clinical symptoms underwent screening.</p></sec><sec id="Section2.6"><title>2.6 Variant verification by Sanger method</title><p>For the validation of variants identified through NGS analysis, gene panel results were analyzed using a designed primers panel. The patient's gDNA was utilized as a template for PCR amplification on a Life Technology (USA) amplification machine, followed by Sanger sequencing analysis on an ABI-3500DX sequencer <xref rid="B15" ref-type="bibr">15</xref>.</p></sec><sec id="Section2.7"><title>2.7 Variant classification and bioinformatics analysis</title><p>We developed an in-house local knowledge base and a proprietary bioinformatics pipeline to automate the construction of classification types for all identified variants and the variant allele frequency was assessed. The clinical significance of all identified variants was assessed following the standards and guidelines of the American College of Medical Genetics and Genomics by ACMG Laboratory Quality Assurance Committee <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B47" ref-type="bibr">47</xref>. Minor allele frequencies were analyzed using public databases including the Exome Aggregation Consortium (ExAC) <xref rid="B48" ref-type="bibr">48</xref>, the 5000 Exomes Project <xref rid="B49" ref-type="bibr">49</xref>, the NHLBI Exome Sequencing Project ESP6500 databases <xref rid="B9" ref-type="bibr">9</xref>, etc. Disease-specific variant information was queried from ClinVar <xref rid="B46" ref-type="bibr">46</xref>, Online Mendelian Inheritance in Man (OMIM) <xref rid="B45" ref-type="bibr">45</xref>, COSMIC <xref rid="B44" ref-type="bibr">44</xref>, etc. The variants were analyzed by silico methodology. Variant substitutions' impact on protein structure and function were predicted using SIFT and PolyPhen-2 tools <xref rid="B43" ref-type="bibr">43</xref>. Nucleotide conservation analysis for all variants was performed by phyloP tool <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B41" ref-type="bibr">41</xref>. An in-house local knowledge base was utilized for classifying, storing, organizing, continuously updating, and upgrading variant information along with lines of evidence. This process ensured reproducibility, rigor, and efficiency in reclassification. Novel variants with our cohort were identified through querying the ExAC database <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B51" ref-type="bibr">51</xref>. In addition, Combined Annotation Dependent Depletion (CADD) (version 1.7) and Mutation Taster tools were also used to analyze these novel variants <xref rid="B52" ref-type="bibr">52</xref>, <xref rid="B53" ref-type="bibr">53</xref>.</p></sec><sec id="Section2.8"><title>2.8 Statistical analyses</title><p>The distribution of gene variants among categories was analyzed by assessing alteration in amino acid function. All statistical analyses were conducted using R software version 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). A statistically significant difference was considered when the adjusted p-value was less than 0.05 <xref rid="B54" ref-type="bibr">54</xref>.</p></sec></sec><sec sec-type="results" id="Section3"><title>3. Results</title><sec id="Section3.1"><title>3.1 The breast cancer patient recruitment and clinical findings</title><p>We enrolled 52 patients with BC tissues and 18 healthy blood donors whose DNA passed quality control for the study [Table <xref rid="T1" ref-type="table">1</xref>]. Clinical information was collected from all patients, with an average age of diagnosis at 50 years (ranging from 29 to 77 years). The average tumor size was measured at 25 mm (range between 10 and 55 mm). Tumor metastasis was observed in 20 patients (38.5%), predominantly diagnosed as invasive ductal breast carcinomas. Patients were categorized into four subtypes based on the expression of Her-2/ER/PR. Among them, Luminal B subtype had the highest prevalence with 23 patients (44.2%), followed by Luminal A subtype with 14 patients (26.9%). Additionally, 11 patients were classified as Her-2-enriched subtype (21.2% in total), and only four patients were identified as basal-like subtype (7.7%). According to the American Cancer Society (<ext-link xlink:href="https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html" ext-link-type="uri">https://www.cancer.org/cancer/types/breast-cancer/about/types-of-breast-cancer.html</ext-link>) and pathological classification of breast cancer (<ext-link xlink:href="https://mp.weixin.qq.com/s/rP6lUKNQWNP96BuMHeik5A" ext-link-type="uri">https://mp.weixin.qq.com/s/rP6lUKNQWNP96BuMHeik5A</ext-link>), the breast cancer cases were divided into two types including <italic>in situ</italic> breast cancer and invasive breast cancer. In addition, we categorized invasive breast cancer into early and late stages [Table <xref rid="T1" ref-type="table">1</xref>]. Moreover, all BC samples were malignant based on the pathologic diagnosis by two independent pathologists. The pathological examination involved H&#x00026;E staining and IHC analysis. Representative H&#x00026;E staining images of normal breast tissue and invasive BC tissue are shown in Figure <xref rid="F2" ref-type="fig">2</xref> A&#x00026;B. Respective IHC images without any antibodies demonstrated negative expression (Figure <xref rid="F2" ref-type="fig">2</xref>C&#x00026;E), while strong positive expressions of BRCA1 and TP53 antibodies were observed in invasive BC tissues (Figure <xref rid="F2" ref-type="fig">2</xref>D&#x00026;F).</p></sec><sec id="Section3.2"><title>3.2 Gene panel design and NGS analysis results</title><p>For the design of gene panel primers, Illumina DesignStudio was utilized and incorporated a total of thirteen genes with 696 primer pairs. The selection of these genes was based on comprehensive analysis using public databases (e.g., COSMIC/ClinVar/HGMD), our previous studies <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B35" ref-type="bibr">35</xref>, as well as a relevant investigation conducted on Chinese breast patients <xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B29" ref-type="bibr">29</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B44" ref-type="bibr">44</xref>-<xref rid="B46" ref-type="bibr">46</xref>. Specifically focusing on the <italic>PIK3CA</italic>, <italic>PIK3R1</italic>, <italic>ESR1</italic>, <italic>TWIST1</italic>, <italic>KMT2C</italic>, <italic>PTEN</italic>, <italic>BRCA2</italic>, <italic>AKT1</italic>, <italic>RNF40</italic>, <italic>PALB2</italic>, <italic>ERBB2</italic>, <italic>TP53</italic>, and <italic>BRCA1</italic> genes, the information about chromosome, exons, and primer pairs is shown in Table <xref rid="T2" ref-type="table">2</xref>. All the genes frequency is about somatic mutations. Germline mutations were excluded. Subsequently, the primers for the panel were synthesized, followed by PCR verification of their specificity. The PCR results for four representative genes (<italic>PTEN/TP53/RNF40/KMT2C</italic>) are illustrated in Figure <xref rid="F3" ref-type="fig">3</xref>.</p><p>After the successful design of the gene panel primers, MPCR amplification was conducted, and subsequent purification of the products was performed. All samples underwent library construction and successfully passed quality control measures, as depicted in Figure <xref rid="F4" ref-type="fig">4</xref>, prior to undergoing NGS. The target fragment distribution of the normal library was between 280 bp and 460 bp, and the main peak was about 391 bp. Through bioinformatics analysis of sequenced data, known various types of variants were identified for each sample [Table <xref rid="T3" ref-type="table">3</xref>].</p></sec><sec id="Section3.3"><title>3.3 Variant verification results</title><p>To validate the genetic variations identified by the gene panel, the Sanger sequencing method was employed to confirm partial variants, and representative outcomes are presented in Figure <xref rid="F5" ref-type="fig">5</xref>. All detected variants were successfully validated through Sanger sequencing. It is worth noting that certain patients exhibited pathogenic variants with SNV peak values less than one-fourth of the allele nucleotide value. Notably, different samples displayed identical variants at the same position with distinct nucleotide types, for instance, samples 7RCa and 36RCa showed <italic>PIK3CA</italic> variant c.3140A&#x0003e;T and c.3140A&#x0003e;G, respectively (Figure <xref rid="F5" ref-type="fig">5</xref> A&#x00026;B). Furthermore, the sequencing results revealed that a single sample harbored multiple variants in different genes; for example, sample 40RCa exhibited <italic>PIK3CA</italic> and <italic>TP53</italic> variants c.3140A&#x0003e;T and c.838A&#x0003e;G, respectively (Figure <xref rid="F5" ref-type="fig">5</xref> C&#x00026;D), while in sample TG02 demonstrated <italic>TP53</italic> and <italic>BRCA1</italic> variant c.497C&#x0003e;G and c.4485-2A&#x0003e;C, respectively (Figure <xref rid="F5" ref-type="fig">5</xref> E&#x00026;F). Additionally, we observed <italic>PALB2</italic> variant c.3054G&#x0003e;C in sample 9RCa, <italic>PIK3CA</italic> variant c.1035T&#x0003e;A in sample 50RCa, as well as <italic>BRCA2</italic> variant c.5985_5986insA in sample TG34, respectively (Figure <xref rid="F5" ref-type="fig">5</xref> G&#x00026;H&#x00026;I).</p></sec><sec id="Section3.4"><title>3.4 Results of different variants' distribution</title><p>By conducting bioinformatics analysis, 4,571 variants were identified in the annotations files from 70 samples and classified into different types (Figure <xref rid="F6" ref-type="fig">6</xref>). All the variants were somatic changes. The predominant type of variants was single nucleotide variation (SNV), accounting for approximately 84.71% (3,872 variants) of the total. The second most common type was insertion and deletion (InDel), comprising about 14.59% (680 variants) of all variants. Additionally, multiple nucleotide variants (MNV) were also observed (Figure <xref rid="F6" ref-type="fig">6</xref>A). Depending on the specific nucleotide alterations, amino acid changes may occur which can potentially impact protein function. These genetic variations were further categorized into various types, including synonymous mutations, missense mutations, frameshift insertion/deletion/block substitution, non-frameshift deletion/block substitution, and other types (Figure <xref rid="F6" ref-type="fig">6</xref>B). Figure <xref rid="F6" ref-type="fig">6</xref>B illustrates that the three most prevalent types of amino acid changes were synonymous mutations, missense mutations, and frameshift insertion with frequencies of 23.54% (1076 variants), 20.46% (935 variants), and 3.24% (148 variants), respectively. Through analyzing the distribution patterns of these variants across different genes and their positions within them (Figure <xref rid="F6" ref-type="fig">6</xref>C), it was found that<italic> KMT2C</italic> gene exhibited the highest number of variant occurrences with a count of around 1484 representing approximately 32.47% of all detected variants. Following this, the gene <italic>BRCA2</italic> displayed the second-highest frequency with 531 variants accounting for 11.62% of all detected variants. The gene <italic>TWIST1</italic> had the lowest number of variants with only 20 around representing approximately 0.44% of all detected variants.</p></sec><sec id="Section3.5"><title>3.5 New variants found in our cohort</title><p>The majority of the variants were identified through comprehensive databases such as ClinVar, OMIM, COSMIC dbsnp, ExAC, etc. Variants that could not be retrieved from these databases were meticulously analyzed and considered for the first time within our cohort. The 358 novel variants (approximately 7.8% of the overall count) were discovered from 52 patients. Subsequently, bioinformatics analysis was conducted to obtain annotation files and classify these variants into distinct types (Figure <xref rid="F7" ref-type="fig">7</xref>). Figure <xref rid="F7" ref-type="fig">7</xref> illustrates that these newly identified variants are distributed among eleven genes, with <italic>KMT2C</italic> gene exhibiting the highest prevalence in 83.0% of samples. Additionally,<italic> BRCA2</italic> (71%), <italic>BRCA1</italic> (48%), <italic>PALB2</italic> (40%), <italic>PIK3CA</italic> (23%), and <italic>RNF40</italic> (21%) genes displayed variant frequencies exceeding 20% of samples. Furthermore, <italic>AKT1</italic> (12%), <italic>ERBB2</italic> (10%), <italic>ESR1</italic> (8%), <italic>TWIST1</italic> (8%), and <italic>PIK3R1</italic> (4%) genes exhibited variant occurrences; however, no new variants were detected in <italic>TP53</italic> and <italic>PTEN</italic> genes.</p><p>Depending on the type of function, missense, frameshift insertion, frameshift deletion, nonsense, and in-frame deletion are observed. Missense variants constitute the predominant type with a total frequency of 40%, followed by frameshift insertion at 23%. The remaining variants collectively account for less than 40% of the occurrences. Notably, certain genes (<italic>KMT2C</italic> and <italic>BRCA2</italic>) exhibit multiple hits as previously mentioned.</p><p>We identified somatic mutations by adding blood samples of healthy individuals to exclude the germline mutations. Based on the sequencing data, the variant allele frequencies were low and all were greater than 2%, which also showed these variants were somatic mutations. PolyPhen-2 and SIFT are commonly employed in-silico tools for missense variant interpretation. A PolyPhen-2 prediction score above 0.3 indicates a probable damaging effect of the variant, resulting in a total of 89 variants (24.9%) out of 358 (52 patients) with a score exceeding this threshold value. Disease-causing (DC) variants exhibit a SIFT value below 0.05, leading to the identification of 101 variants with scores lower than this cutoff among the total number analyzed. Notably, when considering both PolyPhen-2 scores above 0.3 and the SIFT scores below 0.05, a subset of 68 pathogenic variants was found within our cohort consisting of 358 variants across 52 patients [Table <xref rid="T4" ref-type="table">4</xref>]. At the same time, CADD and Mutation Taster tools were also used to analyze these variants. The prediction of the Mutation Taster showed that 74.24% of these variants are disease-causing (exclude 17 polymorphisms) and their corresponding probability value is shown in Table <xref rid="T4" ref-type="table">4</xref>. In addition, 78.79% of the novel variants had a PHRED score greater than 20 in the CADD tool. Taken together, a combination of PolyPhen-2, SIFT, CADD, and Mutation Taster tools' analysis, 49 variants (49/358) had potential pathogenic effects on protein functions and structures across 52 patients. According to the silico prediction, the variants were conserved across different species and not in the germline.</p></sec></sec><sec sec-type="discussion" id="Section4"><title>4. Discussion</title><p>The technology developed for NGS has revolutionized the clinical approach to genetic testing in the field of cancer. Multi-gene panels have demonstrated powerful capabilities in identifying pathogenic variants (PVs) within known BC-related genes, as well as novel variants potentially associated with the disease. Recently, a combination of hereditary gene panels targeting hot mutations such as <italic>BRCA1/2</italic> and <italic>PALB2,</italic> along with multiple genes with various cancers, applied for gene diagnosis <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B38" ref-type="bibr">38</xref>.</p><p>A few of these gene variants were not found in ClinVar, OMIM, and COSMIC databases within the gene panel of variants distribution. Novel mutations were initially discovered in our cohort and confirmed as novel through the ExAC database. Specifically, 68 new variants from PolyPhen-2 and SIFT analysis exhibited potential pathogenicity, providing evidence for ACMG that supports the need for more specific pathogenicity classification when combined with other evidence to enhance clinical application <xref rid="B47" ref-type="bibr">47</xref>. These pathogenic variants increase the risk of BC and offer guidance for early detection/diagnosis. All newly identified variants in the <italic>KMT2C</italic> gene ranked the highest within our cohort, which has been recently reported as a biomarker for chemotherapy response <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B29" ref-type="bibr">29</xref>. The distribution pattern of new variants in <italic>BRCA1/2</italic> genes is as follows: <italic>BRCA1/2</italic> genes are associated with BC pathogenesis and account for approximately 5%-10% of known pathogenic variations among all BC-related genes; they also act as modifiers of hereditary BC risk. Analysis conducted on a large number of Chinese hereditary BC patients revealed that germline variations in the <italic>BRCA1/2</italic> genes exhibit high ethnic specificity <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>, <xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>. The <italic>PALB2</italic> (partner and localizer of <italic>BRCA2</italic>) gene ranks after <italic>KMT2C</italic> and <italic>BRCA1/2</italic> genes among new variants, it encodes a protein that interacts with<italic> BRCA2</italic>, and its mutations are associated with significantly increased female BC risk <xref rid="B11" ref-type="bibr">11</xref>. <italic>PIK3CA</italic> (23%) and <italic>RNF40</italic> (21%) variants were detected in over 20% of samples. The mutation rate of <italic>PIK3CA</italic> is particularly high in male breast cancer (MBC), ranking first among known BC-associated variations recorded in the COSMIC database. Among our patients' cases involving this gene mutation type p. H1047R was predominant <xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B51" ref-type="bibr">51</xref>. In our novel variants of the <italic>RNF40</italic> gene, 19 additional variants were identified, out of which six were classified as DC mutation based on PolyPhen-2 scores greater than 0.3 and SIFT scores less than 0.05. RNF40 has been reported to exhibit both tumor-suppressive and oncogenic roles in BC cells. The occurrence of these gene variants in BC patients has been relatively infrequent <xref rid="B33" ref-type="bibr">33</xref>-<xref rid="B35" ref-type="bibr">35</xref>. Similarly, the distribution of new variants in <italic>AKT1</italic> (12%), <italic>ERBB2</italic> (10%),<italic> ESR1</italic>(8%), <italic>TWIST1</italic>(8%), and <italic>PIK3R1</italic>(4%) genes was found to be less than 15% among all patients <xref rid="B31" ref-type="bibr">31</xref>. These genetic variations across multiple genes pose an increased risk of BC development in humans; however, early detection can facilitate timely diagnosis, prevention, and treatment.</p><p>Variants of the <italic>TP53</italic> and <italic>PTEN</italic> genes were identified in our patient cohort. Additionally, these variants have been associated with an increased susceptibility to cancer development. Tumor protein p53 (TP53), a transcription factor, is a well-known tumor suppressor gene that exhibits high mutation rates across various cancer types, including BC. Although germline in the <italic>TP53</italic> gene is rare and occurs in only approximately 1% of all BC cases, carriers of such mutation face a significantly higher lifetime risk of developing BC, estimated at around 80%-90%, compared to non-carriers <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B30" ref-type="bibr">30</xref>. A recent study has also demonstrated that pathogenic variants in the <italic>PTEN</italic> gene are linked to earlier disease onset and an elevated risk for female BC <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B14" ref-type="bibr">14</xref>.</p><p>Despite extensive research on clinical inhibitors for most high-risk genes with hotspot variants in this gene panel <xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B19" ref-type="bibr">19</xref>-<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B25" ref-type="bibr">25</xref>-<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B50" ref-type="bibr">50</xref>, <xref rid="B55" ref-type="bibr">55</xref>, our study acknowledges certain limitations. The majority of these variants are somatic mutations found in sporadic cases of BC. However, the resistance mechanisms to novel pathogenic variants remain elusive. Therefore, identifying and targeting these pathogenic variants for early BC treatment still presents a significant challenge.</p><p>In our study of the patient tissue with clinical information, we consistently observed a large tumor size, with a maximum diameter of 55 mm, several times larger than that seen in BC patients from Western countries. The average age at diagnosis patients was around 50 years, contrasting with the late age at diagnosis typically observed in developed Western countries. Consequently, patients with tumors were more susceptible to metastasis and recurrence, leading to a decrease in their five-year survival rate <xref rid="B1" ref-type="bibr">1</xref>-<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B10" ref-type="bibr">10</xref>. Early detection, diagnosis, and treatment of BC can improve the survival rate of patients. It is one of the few malignant tumors that can reduce the mortality rate through early diagnosis. Compared with conventional imaging examination, genetic detection has obvious advantages, which can diagnose BC earlier before the appearance of typical clinical manifestations and improve the level of cancer prevention and treatment. Therefore, the novel gene panel based on the high-risk genes may have a high value for the early detection of BC. Currently available data on germline and somatic mutations in BC patients are expanding. Our findings suggest that this novel variant holds significance for early diagnosis/prevention, and treatment strategies specifically tailored for Chinese individuals. Furthermore, it contributes to the overall knowledge base and facilitates clinical applications for diagnosing BC patients as well as providing genetic counseling services for affected families. Notably, utilizing a gene panel for patient gene diagnosis proves cost-effective compared to whole exome sequencing (WES). Compared with general NGS, the gene panel is based on high-risk genes of BC, which has fewer genes and high sequencing depth, easier interpretation, and more efficient detection. This approach not only benefits undeveloped regions of China like some areas in southwest China but also holds potential value for undeveloped countries across Asia or Africa, such as Thailand <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B31" ref-type="bibr">31</xref>, <xref rid="B38" ref-type="bibr">38</xref>.</p></sec><sec sec-type="conclusions" id="Section5"><title>5. Conclusions</title><p>In conclusion, we have preliminarily established a cost-effective and high-risk gene panel for early detection of BC. We found a subset of 49 new pathogenic variants within our cohort consisting of 358 variants across 52 patients on protein functions and structures, and the non-pathogenic variants that may also play a risk factor in BC patients. This breakthrough will contribute to the timely identification, effective prevention, and preventative treatment of BC patients, particularly those residing in developing or undeveloped regions. Moreover, our cohort's discovery of novel pathogenic variants not only enriches the existing knowledge base for clinical application of genetic diagnosis in BC patients but also enhances genetic counseling services pertaining to both BC patients and their family pedigrees.</p></sec></body><back><ack><p>The authors thank the people from Chiang Mai University, the Center of Excellence in Pharmaceutical Nanotechnology, Chiang Mai University, and The Research Center for Preclinical Medicine, Southwest Medical University.</p><sec><title>Funding</title><p>This study was supported by the Special Training Program for Young Science and Technology Talents from Southwest Medical University (No. 00031726), the Key Project of Applied Basic Research of Southwest Medical University (No. 2023ZD010), and the Project Fund for Young Innovative Talents of Huai'an No. 1 Hospital Affiliated to Nanjing Medical University (No. QC202209), and was partially funded by the Sichuan Science and Technology Program (No. 2022YFS0623), National Natural Science Foundation of Sichuan Province (No. 2025ZNSFSC0986), and the National Natural Science Foundation of China (Nos. 82073263 and 31701087).</p></sec><sec><title>Ethics approval and consent to participate</title><p>The study was approved by the Ethical Committee of Southwest Medical University and the Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, and in accordance with the recommendations of the Helsinki Declaration to ensure compliance with ethical standards.</p></sec><sec sec-type="data-availability"><title>Availability of data and materials</title><p>The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.</p></sec><sec><title>Author contributions</title><p>J.F. and S. A. were in charge of the idea, and project design. X. X., L.Y., and L.Z. recruited samples. J. C, C. W., L. Y., X.L., and B.S. performed DNA extraction, MPCR amplification and library construction, and sequencing. J. C, and B.S., performed bioinformatics analysis. S.T. and S.C. performed project design, review, and editing. J.C., J. F., and S. A. wrote and revised the manuscript. All authors read and approved the final manuscript.</p></sec></ack><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><name><surname>Bray</surname><given-names>F</given-names></name><name><surname>Laversanne</surname><given-names>M</given-names></name><name><surname>Sung</surname><given-names>H</given-names></name><name><surname>Ferlay</surname><given-names>J</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Soerjomataram</surname><given-names>I</given-names></name><etal/><article-title>Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><fpage>229</fpage><lpage>63</lpage>
<pub-id pub-id-type="pmid">38572751</pub-id>
</element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Wagle</surname><given-names>NS</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><article-title>Cancer statistics, 2023</article-title><source>CA Cancer J Clin</source><year>2023</year><volume>73</volume><fpage>17</fpage><lpage>48</lpage>
<pub-id pub-id-type="pmid">36633525</pub-id>
</element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><name><surname>Han</surname><given-names>B</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><etal/><article-title>Cancer incidence and mortality in China, 2022</article-title><source>J Natl Cancer Cent</source><year>2024</year><volume>4</volume><fpage>47</fpage><lpage>53</lpage>
<pub-id pub-id-type="pmid">39036382</pub-id>
</element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zou</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><article-title>Female breast cancer statistics of 2010 in China: estimates based on data from 145 population-based cancer registries</article-title><source>J Thorac Dis</source><year>2014</year><volume>6</volume><fpage>466</fpage><lpage>70</lpage>
<pub-id pub-id-type="pmid">24822104</pub-id>
</element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Yu</surname><given-names>ZG</given-names></name><article-title>Current status of breast cancer prevention in China</article-title><source>Chronic Dis Transl Med</source><year>2015</year><volume>1</volume><fpage>2</fpage><lpage>8</lpage>
<pub-id pub-id-type="pmid">29062980</pub-id>
</element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><name><surname>Nagini</surname><given-names>S</given-names></name><article-title>Breast Cancer: Current Molecular Therapeutic Targets and New Players</article-title><source>Anticancer Agents Med Chem</source><year>2017</year><volume>17</volume><fpage>152</fpage><lpage>63</lpage>
<pub-id pub-id-type="pmid">27137076</pub-id>
</element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><collab>Breast Cancer Association C, Dorling L, Carvalho S, Allen J, Gonzalez-Neira A, Luccarini C, et al</collab><article-title>Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>428</fpage><lpage>39</lpage>
<pub-id pub-id-type="pmid">33471991</pub-id>
</element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="other"><article-title>Precision medicine improves outcomes in metastatic breast cancer</article-title>
<source>Nature</source><year>2022</year>
</element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><name><surname>Challis</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Evani</surname><given-names>US</given-names></name><name><surname>Jackson</surname><given-names>AR</given-names></name><name><surname>Paithankar</surname><given-names>S</given-names></name><name><surname>Coarfa</surname><given-names>C</given-names></name><etal/><article-title>An integrative variant analysis suite for whole exome next-generation sequencing data</article-title><source>BMC Bioinformatics</source><year>2012</year><volume>13</volume><fpage>8</fpage>
<pub-id pub-id-type="pmid">22239737</pub-id>
</element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><name><surname>Im</surname><given-names>SA</given-names></name><name><surname>Gennari</surname><given-names>A</given-names></name><name><surname>Park</surname><given-names>YH</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Jiang</surname><given-names>ZF</given-names></name><name><surname>Gupta</surname><given-names>S</given-names></name><etal/><article-title>Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, staging and treatment of patients with metastatic breast cancer</article-title><source>ESMO Open</source><year>2023</year><volume>8</volume><fpage>101541</fpage>
<pub-id pub-id-type="pmid">37178669</pub-id>
</element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Seal</surname><given-names>S</given-names></name><name><surname>Thompson</surname><given-names>D</given-names></name><name><surname>Kelly</surname><given-names>P</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Elliott</surname><given-names>A</given-names></name><etal/><article-title>PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene</article-title><source>Nat Genet</source><year>2007</year><volume>39</volume><fpage>165</fpage><lpage>7</lpage>
<pub-id pub-id-type="pmid">17200668</pub-id>
</element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><name><surname>Heng</surname><given-names>YJ</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Alexandrov</surname><given-names>LB</given-names></name><name><surname>Ambrosone</surname><given-names>CB</given-names></name><name><surname>de Andrade</surname><given-names>VP</given-names></name><etal/><article-title>The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2020</year><volume>29</volume><fpage>599</fpage><lpage>605</lpage>
<pub-id pub-id-type="pmid">31932411</pub-id>
</element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><name><surname>Cummings</surname><given-names>S</given-names></name><name><surname>Alfonso</surname><given-names>A</given-names></name><name><surname>Hughes</surname><given-names>E</given-names></name><name><surname>Kucera</surname><given-names>M</given-names></name><name><surname>Mabey</surname><given-names>B</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><etal/><article-title>Cancer Risk Associated With PTEN Pathogenic Variants Identified Using Multigene Hereditary Cancer Panel Testing</article-title><source>JCO Precis Oncol</source><year>2023</year><volume>7</volume><fpage>e2200415</fpage>
<pub-id pub-id-type="pmid">36634299</pub-id>
</element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><name><surname>Subasioglu</surname><given-names>A</given-names></name><name><surname>Guc</surname><given-names>ZG</given-names></name><name><surname>Gur</surname><given-names>EO</given-names></name><name><surname>Tekindal</surname><given-names>MA</given-names></name><name><surname>Atahan</surname><given-names>MK</given-names></name><article-title>Genetic, Surgical and Oncological Approach to Breast Cancer, with BRCA1, BRCA2, CDH1, PALB2, PTEN and TP53 Variants</article-title><source>Eur J Breast Health</source><year>2023</year><volume>19</volume><fpage>55</fpage><lpage>69</lpage>
<pub-id pub-id-type="pmid">36605468</pub-id>
</element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Khan</surname><given-names>MA</given-names></name><name><surname>Tan</surname><given-names>P</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><etal/><article-title>Identification of a novel germline BRCA2 variant in a Chinese breast cancer family</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><fpage>1676</fpage><lpage>83</lpage>
<pub-id pub-id-type="pmid">31782247</pub-id>
</element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><etal/><article-title>The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis</article-title><source>Cell Res</source><year>2011</year><volume>21</volume><fpage>275</fpage><lpage>89</lpage>
<pub-id pub-id-type="pmid">20714342</pub-id>
</element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><etal/><article-title>COVID-19 disease and malignant cancers: The impact for the furin gene expression in susceptibility to SARS-CoV-2</article-title><source>Int J Biol Sci</source><year>2021</year><volume>17</volume><fpage>3954</fpage><lpage>67</lpage>
<pub-id pub-id-type="pmid">34671211</pub-id>
</element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Maghsoudloo</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><etal/><article-title>Tripartite motif-containing 28 (TRIM28) expression and cordycepin inhibition in progression, prognosis, and therapeutics of patients with breast invasive carcinoma</article-title><source>J Cancer</source><year>2024</year><volume>15</volume><fpage>4374</fpage><lpage>85</lpage>
<pub-id pub-id-type="pmid">38947392</pub-id>
</element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Imani</surname><given-names>S</given-names></name><name><surname>Shasaltaneh</surname><given-names>MD</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><article-title>PIK3CA hotspot mutations p. H1047R and p. H1047L sensitize breast cancer cells to thymoquinone treatment by regulating the PI3K/Akt1 pathway</article-title><source>Mol Biol Rep</source><year>2022</year><volume>49</volume><fpage>1799</fpage><lpage>816</lpage>
<pub-id pub-id-type="pmid">34816327</pub-id>
</element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><name><surname>Jin</surname><given-names>RY</given-names></name><name><surname>Tang</surname><given-names>T</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Long</surname><given-names>X</given-names></name><name><surname>Guo</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><etal/><article-title>Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors</article-title><source>Bioorg Chem</source><year>2020</year><volume>98</volume><fpage>103737</fpage>
<pub-id pub-id-type="pmid">32193031</pub-id>
</element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><name><surname>Tan</surname><given-names>ES</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Al-Toubah</surname><given-names>TE</given-names></name><name><surname>Mehta</surname><given-names>R</given-names></name><name><surname>Centeno</surname><given-names>BA</given-names></name><etal/><article-title>Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers</article-title><source>Cancer</source><year>2021</year><volume>127</volume><fpage>1293</fpage><lpage>300</lpage>
<pub-id pub-id-type="pmid">33289918</pub-id>
</element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><name><surname>Cortesi</surname><given-names>L</given-names></name><name><surname>Rugo</surname><given-names>HS</given-names></name><name><surname>Jackisch</surname><given-names>C</given-names></name><article-title>An Overview of PARP Inhibitors for the Treatment of Breast Cancer</article-title><source>Target Oncol</source><year>2021</year><volume>16</volume><fpage>255</fpage><lpage>82</lpage>
<pub-id pub-id-type="pmid">33710534</pub-id>
</element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><name><surname>Yu</surname><given-names>D</given-names></name><article-title>Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers</article-title><source>Semin Oncol</source><year>2001</year><volume>28</volume><fpage>12</fpage><lpage>7</lpage>
</element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><name><surname>Valabrega</surname><given-names>G</given-names></name><name><surname>Montemurro</surname><given-names>F</given-names></name><name><surname>Aglietta</surname><given-names>M</given-names></name><article-title>Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer</article-title><source>Ann Oncol</source><year>2007</year><volume>18</volume><fpage>977</fpage><lpage>84</lpage>
<pub-id pub-id-type="pmid">17229773</pub-id>
</element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><name><surname>Andrikopoulou</surname><given-names>A</given-names></name><name><surname>Chatzinikolaou</surname><given-names>S</given-names></name><name><surname>Panourgias</surname><given-names>E</given-names></name><name><surname>Kaparelou</surname><given-names>M</given-names></name><name><surname>Liontos</surname><given-names>M</given-names></name><name><surname>Dimopoulos</surname><given-names>MA</given-names></name><etal/><article-title>"The emerging role of capivasertib in breast cancer"</article-title><source>Breast</source><year>2022</year><volume>63</volume><fpage>157</fpage><lpage>67</lpage>
<pub-id pub-id-type="pmid">35398754</pub-id>
</element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><name><surname>Tharin</surname><given-names>Z</given-names></name><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Derangere</surname><given-names>V</given-names></name><name><surname>Ilie</surname><given-names>A</given-names></name><name><surname>Arnould</surname><given-names>L</given-names></name><name><surname>Ghiringhelli</surname><given-names>F</given-names></name><etal/><article-title>PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy</article-title><source>Sci Rep</source><year>2023</year><volume>13</volume><fpage>4467</fpage>
<pub-id pub-id-type="pmid">36934165</pub-id>
</element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><name><surname>Brett</surname><given-names>JO</given-names></name><name><surname>Spring</surname><given-names>LM</given-names></name><name><surname>Bardia</surname><given-names>A</given-names></name><name><surname>Wander</surname><given-names>SA</given-names></name><article-title>ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer</article-title><source>Breast Cancer Res</source><year>2021</year><volume>23</volume><fpage>85</fpage>
<pub-id pub-id-type="pmid">34392831</pub-id>
</element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><name><surname>Berger</surname><given-names>F</given-names></name><name><surname>Marce</surname><given-names>M</given-names></name><name><surname>Delaloge</surname><given-names>S</given-names></name><name><surname>Hardy-Bessard</surname><given-names>AC</given-names></name><name><surname>Bachelot</surname><given-names>T</given-names></name><name><surname>Bieche</surname><given-names>I</given-names></name><etal/><article-title>Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1</article-title><source>BMJ Open</source><year>2022</year><volume>12</volume><fpage>e055821</fpage>
</element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qiu</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Meng</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Ji</surname><given-names>J</given-names></name><etal/><article-title>KMT2C is a potential biomarker of prognosis and chemotherapy sensitivity in breast cancer</article-title><source>Breast Cancer Res Treat</source><year>2021</year><volume>189</volume><fpage>347</fpage><lpage>61</lpage>
<pub-id pub-id-type="pmid">34240274</pub-id>
</element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><name><surname>Kwong</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>VY</given-names></name><name><surname>Ho</surname><given-names>CYS</given-names></name><name><surname>Au</surname><given-names>CH</given-names></name><name><surname>Slavin</surname><given-names>TP</given-names></name><name><surname>Weitzel</surname><given-names>JN</given-names></name><etal/><article-title>Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients</article-title><source>BMC Cancer</source><year>2020</year><volume>20</volume><fpage>1053</fpage>
<pub-id pub-id-type="pmid">33138793</pub-id>
</element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Lai</surname><given-names>J</given-names></name><etal/><article-title>Characterization of Frequently Mutated Cancer Genes and Tumor Mutation Burden in Chinese Breast Cancer</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>618767</fpage>
<pub-id pub-id-type="pmid">33968723</pub-id>
</element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><name><surname>Guindalini</surname><given-names>RSC</given-names></name><name><surname>Viana</surname><given-names>DV</given-names></name><name><surname>Kitajima</surname><given-names>J</given-names></name><name><surname>Rocha</surname><given-names>VM</given-names></name><name><surname>Lopez</surname><given-names>RVM</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><etal/><article-title>Detection of germline variants in Brazilian breast cancer patients using multigene panel testing</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><fpage>4190</fpage>
<pub-id pub-id-type="pmid">35264596</pub-id>
</element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/><article-title>Development of diagnostic SCAR markers for genomic DNA amplifications in breast carcinoma by DNA cloning of high-GC RAMP-PCR fragments</article-title><source>Oncotarget</source><year>2017</year><volume>8</volume><fpage>43866</fpage><lpage>77</lpage>
<pub-id pub-id-type="pmid">28410206</pub-id>
</element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><name><surname>Tarcic</surname><given-names>O</given-names></name><name><surname>Granit</surname><given-names>RZ</given-names></name><name><surname>Pateras</surname><given-names>IS</given-names></name><name><surname>Masury</surname><given-names>H</given-names></name><name><surname>Maly</surname><given-names>B</given-names></name><name><surname>Zwang</surname><given-names>Y</given-names></name><etal/><article-title>RNF20 and histone H2B ubiquitylation exert opposing effects in Basal-Like versus luminal breast cancer</article-title><source>Cell Death Differ</source><year>2017</year><volume>24</volume><fpage>694</fpage><lpage>704</lpage>
<pub-id pub-id-type="pmid">28157208</pub-id>
</element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="journal"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Liao</surname><given-names>L</given-names></name><name><surname>Balaji</surname><given-names>KS</given-names></name><name><surname>Wei</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><article-title>Epigenetic modification and a role for the E3 ligase RNF40 in cancer development and metastasis</article-title><source>Oncogene</source><year>2021</year><volume>40</volume><fpage>465</fpage><lpage>74</lpage>
<pub-id pub-id-type="pmid">33199825</pub-id>
</element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><name><surname>Slavin</surname><given-names>TP</given-names></name><name><surname>Niell-Swiller</surname><given-names>M</given-names></name><name><surname>Solomon</surname><given-names>I</given-names></name><name><surname>Nehoray</surname><given-names>B</given-names></name><name><surname>Rybak</surname><given-names>C</given-names></name><name><surname>Blazer</surname><given-names>KR</given-names></name><etal/><article-title>Corrigendum: Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management</article-title><source>Front Oncol</source><year>2015</year><volume>5</volume><fpage>271</fpage>
<pub-id pub-id-type="pmid">26697406</pub-id>
</element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><name><surname>Tung</surname><given-names>N</given-names></name><name><surname>Battelli</surname><given-names>C</given-names></name><name><surname>Allen</surname><given-names>B</given-names></name><name><surname>Kaldate</surname><given-names>R</given-names></name><name><surname>Bhatnagar</surname><given-names>S</given-names></name><name><surname>Bowles</surname><given-names>K</given-names></name><etal/><article-title>Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel</article-title><source>Cancer</source><year>2015</year><volume>121</volume><fpage>25</fpage><lpage>33</lpage>
<pub-id pub-id-type="pmid">25186627</pub-id>
</element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><name><surname>Gardner</surname><given-names>SA</given-names></name><name><surname>Weymouth</surname><given-names>KS</given-names></name><name><surname>Kelly</surname><given-names>WS</given-names></name><name><surname>Bogdanova</surname><given-names>E</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Lupu</surname><given-names>D</given-names></name><etal/><article-title>Evaluation of a 27-gene inherited cancer panel across 630 consecutive patients referred for testing in a clinical diagnostic laboratory</article-title><source>Hered Cancer Clin Pract</source><year>2018</year><volume>16</volume><fpage>1</fpage>
<pub-id pub-id-type="pmid">29308099</pub-id>
</element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><name><surname>Watahiki</surname><given-names>M</given-names></name><name><surname>Kawahara</surname><given-names>R</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Aoki</surname><given-names>M</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><name><surname>Matsumoto</surname><given-names>Y</given-names></name><etal/><article-title>Single-Tube Multiplex Polymerase Chain Reaction for the Detection of Genes Encoding Enterobacteriaceae Carbapenemase</article-title><source>Jpn J Infect Dis</source><year>2020</year><volume>73</volume><fpage>166</fpage><lpage>72</lpage>
<pub-id pub-id-type="pmid">31787735</pub-id>
</element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Durbin</surname><given-names>R</given-names></name><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>1754</fpage><lpage>60</lpage>
<pub-id pub-id-type="pmid">19451168</pub-id>
</element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><name><surname>McKenna</surname><given-names>A</given-names></name><name><surname>Hanna</surname><given-names>M</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Sivachenko</surname><given-names>A</given-names></name><name><surname>Cibulskis</surname><given-names>K</given-names></name><name><surname>Kernytsky</surname><given-names>A</given-names></name><etal/><article-title>The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data</article-title><source>Genome Res</source><year>2010</year><volume>20</volume><fpage>1297</fpage><lpage>303</lpage>
<pub-id pub-id-type="pmid">20644199</pub-id>
</element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><article-title>ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data</article-title><source>Nucleic Acids Res</source><year>2010</year><volume>38</volume><fpage>e164</fpage>
<pub-id pub-id-type="pmid">20601685</pub-id>
</element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><name><surname>Ng</surname><given-names>PC</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name><article-title>SIFT: Predicting amino acid changes that affect protein function</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><fpage>3812</fpage><lpage>4</lpage>
<pub-id pub-id-type="pmid">12824425</pub-id>
</element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><name><surname>Bamford</surname><given-names>S</given-names></name><name><surname>Dawson</surname><given-names>E</given-names></name><name><surname>Forbes</surname><given-names>S</given-names></name><name><surname>Clements</surname><given-names>J</given-names></name><name><surname>Pettett</surname><given-names>R</given-names></name><name><surname>Dogan</surname><given-names>A</given-names></name><etal/><article-title>The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>355</fpage><lpage>8</lpage>
<pub-id pub-id-type="pmid">15188009</pub-id>
</element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><name><surname>Amberger</surname><given-names>JS</given-names></name><name><surname>Bocchini</surname><given-names>CA</given-names></name><name><surname>Schiettecatte</surname><given-names>F</given-names></name><name><surname>Scott</surname><given-names>AF</given-names></name><name><surname>Hamosh</surname><given-names>A</given-names></name><article-title>OMIM.org: Online Mendelian Inheritance in Man (OMIM(R)), an online catalog of human genes and genetic disorders</article-title><source>Nucleic Acids Res</source><year>2015</year><volume>43</volume><fpage>D789</fpage><lpage>98</lpage>
<pub-id pub-id-type="pmid">25428349</pub-id>
</element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><name><surname>Landrum</surname><given-names>MJ</given-names></name><name><surname>Lee</surname><given-names>JM</given-names></name><name><surname>Benson</surname><given-names>M</given-names></name><name><surname>Brown</surname><given-names>GR</given-names></name><name><surname>Chao</surname><given-names>C</given-names></name><name><surname>Chitipiralla</surname><given-names>S</given-names></name><etal/><article-title>ClinVar: improving access to variant interpretations and supporting evidence</article-title><source>Nucleic Acids Res</source><year>2018</year><volume>46</volume><fpage>D1062</fpage><lpage>D7</lpage>
<pub-id pub-id-type="pmid">29165669</pub-id>
</element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><name><surname>Richards</surname><given-names>S</given-names></name><name><surname>Aziz</surname><given-names>N</given-names></name><name><surname>Bale</surname><given-names>S</given-names></name><name><surname>Bick</surname><given-names>D</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Gastier-Foster</surname><given-names>J</given-names></name><etal/><article-title>Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology</article-title><source>Genet Med</source><year>2015</year><volume>17</volume><fpage>405</fpage><lpage>24</lpage>
<pub-id pub-id-type="pmid">25741868</pub-id>
</element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><name><surname>Lek</surname><given-names>M</given-names></name><name><surname>Karczewski</surname><given-names>KJ</given-names></name><name><surname>Minikel</surname><given-names>EV</given-names></name><name><surname>Samocha</surname><given-names>KE</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><etal/><article-title>Analysis of protein-coding genetic variation in 60,706 humans</article-title><source>Nature</source><year>2016</year><volume>536</volume><fpage>285</fpage><lpage>91</lpage>
<pub-id pub-id-type="pmid">27535533</pub-id>
</element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><name><surname>Genomes Project</surname><given-names>C</given-names></name><name><surname>Auton</surname><given-names>A</given-names></name><name><surname>Brooks</surname><given-names>LD</given-names></name><name><surname>Durbin</surname><given-names>RM</given-names></name><name><surname>Garrison</surname><given-names>EP</given-names></name><name><surname>Kang</surname><given-names>HM</given-names></name><etal/><article-title>A global reference for human genetic variation</article-title><source>Nature</source><year>2015</year><volume>526</volume><fpage>68</fpage><lpage>74</lpage>
<pub-id pub-id-type="pmid">26432245</pub-id>
</element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><name><surname>Pollard</surname><given-names>KS</given-names></name><name><surname>Hubisz</surname><given-names>MJ</given-names></name><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Siepel</surname><given-names>A</given-names></name><article-title>Detection of nonneutral substitution rates on mammalian phylogenies</article-title><source>Genome Res</source><year>2010</year><volume>20</volume><fpage>110</fpage><lpage>21</lpage>
<pub-id pub-id-type="pmid">19858363</pub-id>
</element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><name><surname>Hutchinson</surname><given-names>KE</given-names></name><name><surname>Chen</surname><given-names>JW</given-names></name><name><surname>Savage</surname><given-names>HM</given-names></name><name><surname>Stout</surname><given-names>TJ</given-names></name><name><surname>Schimmoller</surname><given-names>F</given-names></name><name><surname>Cortes</surname><given-names>J</given-names></name><etal/><article-title>Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers</article-title><source>Genome Med</source><year>2023</year><volume>15</volume><fpage>28</fpage>
<pub-id pub-id-type="pmid">37101291</pub-id>
</element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><name><surname>Schubach</surname><given-names>M</given-names></name><name><surname>Maass</surname><given-names>T</given-names></name><name><surname>Nazaretyan</surname><given-names>L</given-names></name><name><surname>Roner</surname><given-names>S</given-names></name><name><surname>Kircher</surname><given-names>M</given-names></name><article-title>CADD v1.7: using protein language models, regulatory CNNs and other nucleotide-level scores to improve genome-wide variant predictions</article-title><source>Nucleic Acids Res</source><year>2024</year><volume>52</volume><fpage>D1143</fpage><lpage>D54</lpage>
<pub-id pub-id-type="pmid">38183205</pub-id>
</element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><name><surname>Schwarz</surname><given-names>JM</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Schuelke</surname><given-names>M</given-names></name><name><surname>Seelow</surname><given-names>D</given-names></name><article-title>MutationTaster2: mutation prediction for the deep-sequencing age</article-title><source>Nat Methods</source><year>2014</year><volume>11</volume><fpage>361</fpage><lpage>2</lpage>
<pub-id pub-id-type="pmid">24681721</pub-id>
</element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="other"><collab>R Core Team</collab><article-title>R: A language and environment for statistical computing</article-title>
<source>Vienna: R Foundation for statistical Computing</source><year>2018</year>
</element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Maghsoudloo</surname><given-names>M</given-names></name><name><surname>Cheng</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>J</given-names></name><article-title>Comprehensive analysis, diagnosis, prognosis, and cordycepin (CD) regulations for GSDME expressions in pan-cancers</article-title><source>Cancer Cell Int</source><year>2024</year><volume>24</volume><fpage>279</fpage>
<pub-id pub-id-type="pmid">39118110</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="F1"><label>Figure 1</label><caption><p>The workflow of our study and gene panel design is as follows. A. Study workflow - firstly, we collected BC tissue from patients and blood samples from normal individuals. Subsequently, DNA was extracted, followed by use of 13 genes in the design panel. Multiple-PCR was completed and the product was purified. Then, a DNA library was constructed, quality control checks were performed using Agilent 5200, and sequencing was carried out using the Illumina Miseq platform. Thirdly, bioinformatics analysis of sequencing data obtained all variants which validated using the Sanger method before applying for diagnosis and genetic counseling through the panel. B. Gene panel design workflow - firstly public databases (e.g., Cosmic/SNP/ClinVar) were analyzed along with commercial BC panels to choose risk genes for designing our gene panel. Secondly, Illumina DesignStudio designed gene panels while setting primer parameters. Thirdly, synthesized primers underwent PCR validation to ensure specificity. Finally, the successful construction of our gene panel.</p></caption><graphic xlink:href="jcav16p1281g001" position="float"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Results of H&#x00026;E staining images and representative IHC images are presented. A. H&#x00026;E staining image depicting normal breast tissue is shown. B. H&#x00026;E staining image illustrating invasive BC tissue is displayed. C. Representative IHC image demonstrating the absence of BRCA1 antibody in invasive BC tissues is provided. D. Representative IHC image displaying the presence of BRCA1 antibody in invasive BC tissues is included. E. Representative IHC image indicating the lack of TP53 antibody in invasive BC tissues is depicted. F Representative IHC image showing the presence of TP53 antibody in invasive BC tissues is exhibited. H&#x00026;E: Hematoxylin &#x00026;Eosin; IHC: immunohistochemical staining.</p></caption><graphic xlink:href="jcav16p1281g002" position="float"/></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Exemplary PCR results were achieved using gene panel primers. A. <italic>PTEN</italic> gene with partial primers. B. <italic>TP53</italic> gene with total primers. C. <italic>RNF40</italic> gene with partial primers. D. <italic>KMT2C</italic> gene with partial primers.</p></caption><graphic xlink:href="jcav16p1281g003" position="float"/></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Representative quality score profiles for different samples were generated using Agilent technology. A&#x00026;B&#x00026;C&#x00026;D. The quality score was determined for sample 2RCa, sample 7RCa, sample 9RCa, sample 20RCa, respectively.</p></caption><graphic xlink:href="jcav16p1281g004" position="float"/></fig><fig position="float" id="F5"><label>Figure 5</label><caption><p>Representative program profiles for variant verification by Sanger sequencing are presented as follows: A. The Sanger sequencing results of sample 7RCa reveal the presence of <italic>PIK3CA</italic> variant c.3140A&#x0003e;T. B. In sample 36RCa, the Sanger sequencing results indicate the occurrence of <italic>PIK3CA</italic> variant c.3140A&#x0003e;G. C&#x00026;D. Sample 40RCa exhibits two variants, namely <italic>PIK3CA</italic> variant c.3140A&#x0003e;T and <italic>TP53</italic> variant c.838A&#x0003e;G, as confirmed by Sanger sequencing. E&#x00026;F. The Sanger sequencing analysis of sample TG02 identifies <italic>TP53</italic> variant c.497C&#x0003e;G and <italic>BRCA1</italic> variant c.4485-2A&#x0003e;C. G. The <italic>PALB2</italic> variant c.3054G&#x0003e;C is detected in sample 9RCa through Sanger sequencing. H. In sample 50RCa, a <italic>PIK3CA</italic> variant c.1035T&#x0003e;A is identified using Sanger sequencing. I. Sample TG34 shows an insertion mutation (<italic>BRCA2</italic> variant c.5985_5986insA) according to the results obtained from Sanger sequencing.</p></caption><graphic xlink:href="jcav16p1281g005" position="float"/></fig><fig position="float" id="F6"><label>Figure 6</label><caption><p>Results of different variants of the panel encompassing 13 genes examined in a cohort comprising 52 distinct breast cancer samples and individuals without the disease. A. Distribution analysis was conducted for missense, nonsense, synonymous, and intron mutation. B. The SNV, InDel, and MNV distribution was also investigated. C. Comprehensive assessment of all variant types within our gene panel was performed. Abbreviations: SNV: Single nucleotide variant; InDel: Insertion-Deletion; MNV: Multiple Nucleotide Variant.</p></caption><graphic xlink:href="jcav16p1281g006" position="float"/></fig><fig position="float" id="F7"><label>Figure 7</label><caption><p>The distribution of all new variants in 11 genes (<italic>KMT2C</italic> (83.0%), <italic>BRCA2</italic>(71%), <italic>BRCA1</italic> (48%), <italic>PALB2</italic>(40%), <italic>PIK3CA</italic> (23%), <italic>RNF40</italic> (21%), <italic>AKT1</italic> (12%), <italic>ERBB2</italic> (10%), <italic>ESR1</italic> (8%), <italic>TWIST1</italic> (8%) and <italic>PIK3R1</italic> (4%)) was observed in a cohort of 52 patients. Notably, no new variant was identified in <italic>TP53</italic> and <italic>PTEN</italic> genes. These variants were classified into different types, including Missense_mutation, Frame_Shift_Ins, Frame_Shift_Del, Nonsense_mutation, and In_Frame_Del. Additionally, the samples were categorized into three groups: in situ breast cancer with 5 patients, invasive breast cancer (early-stage) with 30 patients, and invasive breast cancer (late-stage) with 17 patients. Abbreviations: Frame_Shift_Ins: Frameshift insertion; Frame_Shift_Del: Frame shift deletion; In_Frame_Del: Inframe deletion; Multi_Hit: Multiple Hit.</p></caption><graphic xlink:href="jcav16p1281g007" position="float"/></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Demographic summary of the study group</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1">Number (n)</th><th rowspan="1" colspan="1">Percentage (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Gender</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Female</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">92.8</td></tr><tr><td rowspan="1" colspan="1">Male</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">7.2</td></tr><tr><td rowspan="1" colspan="1">
<bold>Cancer</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Yes</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">74.3</td></tr><tr><td rowspan="1" colspan="1">No</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">25.7</td></tr><tr><td rowspan="1" colspan="1">
<bold>Age of onset</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">&#x0003c;40 years</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">18.6%</td></tr><tr><td rowspan="1" colspan="1">&#x0003e;40 years</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">82.4%</td></tr><tr><td rowspan="1" colspan="1">
<bold>Intrinsic molecular subtype of breast cancer patients</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Luminal A</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">26.9%</td></tr><tr><td rowspan="1" colspan="1">Luminal B</td><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">44.2%</td></tr><tr><td rowspan="1" colspan="1">HER2- enriched</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">21.2%</td></tr><tr><td rowspan="1" colspan="1">Basal-like</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">7.7%</td></tr><tr><td rowspan="1" colspan="1">
<bold>Types of breast cancer</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">in situ breast cancer</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">9.6%</td></tr><tr><td rowspan="1" colspan="1">invasive breast cancer (early-stage)</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">57.7%</td></tr><tr><td rowspan="1" colspan="1">invasive breast cancer (late-stage)</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">32.7%</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>List of genes analyzed and their association with breast cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Transcript</th><th rowspan="1" colspan="1">Chromosome</th><th rowspan="1" colspan="1">Num_primers</th><th rowspan="1" colspan="1">Num_exons</th><th rowspan="1" colspan="1">Alteration</th><th rowspan="1" colspan="1">Frequency (%)</th><th rowspan="1" colspan="1">Candidate drug</th><th rowspan="1" colspan="1">Level of evidence for the target</th><th rowspan="1" colspan="1">Gene function/signal pathway</th><th rowspan="1" colspan="1">Specific inhibitors</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">NM_006218.4</td><td rowspan="1" colspan="1">chr3</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">Amplifications/Mutations</td><td rowspan="1" colspan="1">&#x0003e;10</td><td rowspan="1" colspan="1">PI3K inhibitor</td><td rowspan="1" colspan="1">1-2</td><td rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td rowspan="1" colspan="1">Alpelisib (FDA-approved), Copanlisib (clinical trial)</td></tr><tr><td rowspan="1" colspan="1">
<italic>PIK3R1</italic>
</td><td rowspan="1" colspan="1">NM_181523.3</td><td rowspan="1" colspan="1">chr5</td><td rowspan="1" colspan="1">57</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">Mutations</td><td rowspan="1" colspan="1">1-5</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>ESR1</italic>
</td><td rowspan="1" colspan="1">NM_001122740.2</td><td rowspan="1" colspan="1">chr6</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">Mutations/Amplifications/Translocations</td><td rowspan="1" colspan="1">&#x0003e;10% in metastatic/ER+ MBC resistant to endocrine therapy</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">ER signaling</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">NM_170606.3</td><td rowspan="1" colspan="1">chr7</td><td rowspan="1" colspan="1">145</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">Mutations</td><td rowspan="1" colspan="1">5-10</td><td rowspan="1" colspan="1">Drug targeting/epigenetics</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">Epigenetics</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>PTEN</italic>
</td><td rowspan="1" colspan="1">NM_000314.8</td><td rowspan="1" colspan="1">chr10</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">Mutations/Deletions</td><td rowspan="1" colspan="1">5-10</td><td rowspan="1" colspan="1">AKT inhibitor</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td rowspan="1" colspan="1">Copanlisib (clinical trial)</td></tr><tr><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">NM_000059.4</td><td rowspan="1" colspan="1">chr13</td><td rowspan="1" colspan="1">82</td><td rowspan="1" colspan="1">27</td><td rowspan="1" colspan="1">Mutations/Deletions</td><td rowspan="1" colspan="1">1-5</td><td rowspan="1" colspan="1">PARP inhibitor</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">DNA repair</td><td rowspan="1" colspan="1">Rucaparib, Niraparib, Olaparib (FDA-approved)</td></tr><tr><td rowspan="1" colspan="1">
<italic>AKT1</italic>
</td><td rowspan="1" colspan="1">NM_001014431.2</td><td rowspan="1" colspan="1">chr14</td><td rowspan="1" colspan="1">30</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">Amplifications/Mutations</td><td rowspan="1" colspan="1">1-5</td><td rowspan="1" colspan="1">AKT inhibitor</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">PI3K/AKT/mTOR</td><td rowspan="1" colspan="1">Capivasertib (AZD-5363, clinical trial)</td></tr><tr><td rowspan="1" colspan="1">
<italic>ERBB2</italic>
</td><td rowspan="1" colspan="1">NM_004448.4</td><td rowspan="1" colspan="1">chr17</td><td rowspan="1" colspan="1">60</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">Amplifications/Mutations</td><td rowspan="1" colspan="1">&#x0003e;10</td><td rowspan="1" colspan="1">HER2 inhibitor</td><td rowspan="1" colspan="1">1/3</td><td rowspan="1" colspan="1">Growth factor receptors</td><td rowspan="1" colspan="1">Trastuzumab (FDA-approved)</td></tr><tr><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">NM_000546.6</td><td rowspan="1" colspan="1">chr17</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">Mutations</td><td rowspan="1" colspan="1">&#x0003e;10</td><td rowspan="1" colspan="1">Not known</td><td rowspan="1" colspan="1">NA</td><td rowspan="1" colspan="1">DNA repair</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">NM_007294.4</td><td rowspan="1" colspan="1">chr17</td><td rowspan="1" colspan="1">56</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">Mutations/Deletions</td><td rowspan="1" colspan="1">1-5</td><td rowspan="1" colspan="1">PARP inhibitor</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">DNA repair</td><td rowspan="1" colspan="1">Rucaparib, Niraparib, Olaparib (FDA-approved)</td></tr><tr><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">NM_000474.4</td><td rowspan="1" colspan="1">chr7</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">NM_014771.4</td><td rowspan="1" colspan="1">chr16</td><td rowspan="1" colspan="1">48</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">NM_024675.4</td><td rowspan="1" colspan="1">chr16</td><td rowspan="1" colspan="1">32</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Known pathogenic variants result</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Type</th><th rowspan="1" colspan="1">Genotype</th><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">Exon</th><th rowspan="1" colspan="1">Protein</th><th rowspan="1" colspan="1">Coding</th><th rowspan="1" colspan="1">ClinVar</th><th rowspan="1" colspan="1">Chromosome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">2RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/T</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Leu</td><td rowspan="1" colspan="1">c.3140A&#x0003e;T</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">20RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">26RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">36RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">CA/CG</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952084</td></tr><tr><td rowspan="1" colspan="1">40RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">ATC/GTC</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">40RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">T/C</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">p.Arg280Gly</td><td rowspan="1" colspan="1">c.838A&#x0003e;G</td><td rowspan="1" colspan="1">Conflicting Interpretations of pathogenicity</td><td rowspan="1" colspan="1">chr17:7577100</td></tr><tr><td rowspan="1" colspan="1">42RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">TG15</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">ACA/ACG</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952083</td></tr><tr><td rowspan="1" colspan="1">TG19</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/G</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Arg</td><td rowspan="1" colspan="1">c.3140A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">TG46</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">A/T</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.His1047Leu</td><td rowspan="1" colspan="1">c.3140A&#x0003e;T</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178952085</td></tr><tr><td rowspan="1" colspan="1">9RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">C/G</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Glu1018Asp</td><td rowspan="1" colspan="1">c.3054G&#x0003e;C</td><td rowspan="1" colspan="1">Conflicting Interpretations of pathogenicity</td><td rowspan="1" colspan="1">chr16:23632742</td></tr><tr><td rowspan="1" colspan="1">27RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">C/T</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">nonsense</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">p.Trp53Ter</td><td rowspan="1" colspan="1">c.158G&#x0003e;A</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr17:7579529</td></tr><tr><td rowspan="1" colspan="1">31RCa</td><td rowspan="1" colspan="1">INDEL</td><td rowspan="1" colspan="1">GTTTA/G</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">frameshiftDeletion</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Ile591MetfsTer22</td><td rowspan="1" colspan="1">c.1773_1776delTTAT</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr13:32907382</td></tr><tr><td rowspan="1" colspan="1">50RCa</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">T/A</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">p.Asn345Lys</td><td rowspan="1" colspan="1">c.1035T&#x0003e;A</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr3:178921553</td></tr><tr><td rowspan="1" colspan="1">TG02</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">G/C</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">nonsense</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">p.Ser166Ter</td><td rowspan="1" colspan="1">c.497C&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr17:7578433</td></tr><tr><td rowspan="1" colspan="1">TG02</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">T/G</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">unknown</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">p.?</td><td rowspan="1" colspan="1">c.4485-2A&#x0003e;C</td><td rowspan="1" colspan="1">Likely pathogenic</td><td rowspan="1" colspan="1">chr17:41226540</td></tr><tr><td rowspan="1" colspan="1">TG04</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">C/T</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">nonsense</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">p.Trp91Ter</td><td rowspan="1" colspan="1">c.273G&#x0003e;A</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr17:7579414</td></tr><tr><td rowspan="1" colspan="1">TG34</td><td rowspan="1" colspan="1">INDEL</td><td rowspan="1" colspan="1">CAAAAC/CAAAACA</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">frameshiftInsertion</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Ala1996SerfsTer7</td><td rowspan="1" colspan="1">c.5985_5986insA</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr13:32914472</td></tr><tr><td rowspan="1" colspan="1">TG38</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">T/C</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">p.Tyr163Cys</td><td rowspan="1" colspan="1">c.488A&#x0003e;G</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr17:7578442</td></tr><tr><td rowspan="1" colspan="1">TG39</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">G/A</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">p.Arg38His</td><td rowspan="1" colspan="1">c.113G&#x0003e;A</td><td rowspan="1" colspan="1">Likely pathogenic</td><td rowspan="1" colspan="1">chr3:178916726</td></tr><tr><td rowspan="1" colspan="1">TG40</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">C/T</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">p.Gly245Ser</td><td rowspan="1" colspan="1">c.733G&#x0003e;A</td><td rowspan="1" colspan="1">Pathogenic</td><td rowspan="1" colspan="1">chr17:7577548</td></tr><tr><td rowspan="1" colspan="1">TG52</td><td rowspan="1" colspan="1">SNV</td><td rowspan="1" colspan="1">G/C</td><td rowspan="1" colspan="1">
<italic>TP53</italic>
</td><td rowspan="1" colspan="1">missense</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">p.His193Asp</td><td rowspan="1" colspan="1">c.577C&#x0003e;G</td><td rowspan="1" colspan="1">Likely pathogenic</td><td rowspan="1" colspan="1">chr17:7578272</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Results of new probable damaging variants found in our cohort</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Gene</th><th rowspan="1" colspan="1">Chromosome</th><th rowspan="1" colspan="1">Function</th><th rowspan="1" colspan="1">Exon</th><th rowspan="1" colspan="1">Protein</th><th rowspan="1" colspan="1">Coding</th><th rowspan="1" colspan="1">Variant Allele Frequency</th><th rowspan="1" colspan="1">Sift</th><th rowspan="1" colspan="1">Polyphen</th><th rowspan="1" colspan="1">MutationTaster</th><th rowspan="1" colspan="1">PHRED</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">2RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151949631</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Arg490Gly</td><td rowspan="1" colspan="1">c.1468A&#x0003e;G</td><td rowspan="1" colspan="1">2.94%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">19.31</td></tr><tr><td rowspan="1" colspan="1">2RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32914067</td><td rowspan="1" colspan="1">Non_Synonymous_Mutation</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Lys1861=;Val1862Met</td><td rowspan="1" colspan="1">c.5583_5584delAGinsGA</td><td rowspan="1" colspan="1">3.64%</td><td rowspan="1" colspan="1">0.04</td><td rowspan="1" colspan="1">0.937</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">-</td></tr><tr><td rowspan="1" colspan="1">7RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32906985</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Lys457Arg</td><td rowspan="1" colspan="1">c.1370A&#x0003e;G</td><td rowspan="1" colspan="1">6.58%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.949</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">17.19</td></tr><tr><td rowspan="1" colspan="1">9RCa-1</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32906459</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.His282Asn</td><td rowspan="1" colspan="1">c.844C&#x0003e;A</td><td rowspan="1" colspan="1">4.17%</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.723</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">6.942</td></tr><tr><td rowspan="1" colspan="1">10RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151960147</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">p.Leu418Pro</td><td rowspan="1" colspan="1">c.1253T&#x0003e;C</td><td rowspan="1" colspan="1">3.51%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">28.6</td></tr><tr><td rowspan="1" colspan="1">11RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151880075</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">35</td><td rowspan="1" colspan="1">p.Glu1750Gly</td><td rowspan="1" colspan="1">c.5249A&#x0003e;G</td><td rowspan="1" colspan="1">3.57%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.5</td></tr><tr><td rowspan="1" colspan="1">11RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32893237</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">p.Trp31Arg</td><td rowspan="1" colspan="1">c.91T&#x0003e;A</td><td rowspan="1" colspan="1">22.49%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="1" colspan="1">11RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23619317</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">p.Val1073Ala</td><td rowspan="1" colspan="1">c.3218T&#x0003e;C</td><td rowspan="1" colspan="1">3.45%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.994</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">24.2</td></tr><tr><td rowspan="1" colspan="1">12RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151853395</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">p.Ser3903Pro</td><td rowspan="1" colspan="1">c.11707T&#x0003e;C</td><td rowspan="1" colspan="1">2.56%</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.8</td></tr><tr><td rowspan="1" colspan="1">12RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151873368</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">p.Asp3057Gly</td><td rowspan="1" colspan="1">c.9170A&#x0003e;G</td><td rowspan="1" colspan="1">2.9%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.0</td></tr><tr><td rowspan="1" colspan="1">12RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151874022</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">p.Glu2838Val</td><td rowspan="1" colspan="1">c.8513A&#x0003e;T</td><td rowspan="1" colspan="1">3.13%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.895</td><td rowspan="1" colspan="1">0.994</td><td rowspan="1" colspan="1">21.7</td></tr><tr><td rowspan="1" colspan="1">13RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614913</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Leu1143Pro</td><td rowspan="1" colspan="1">c.3428T&#x0003e;C</td><td rowspan="1" colspan="1">2.67%</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.562</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">24.7</td></tr><tr><td rowspan="1" colspan="1">16RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151833939</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">p.Asn4905Ser</td><td rowspan="1" colspan="1">c.14714A&#x0003e;G</td><td rowspan="1" colspan="1">2.94%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.997</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.9</td></tr><tr><td rowspan="1" colspan="1">17RCa</td><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">chr7:19156497</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">p.Lys150Glu</td><td rowspan="1" colspan="1">c.448A&#x0003e;G</td><td rowspan="1" colspan="1">5.36%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.993</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">32</td></tr><tr><td rowspan="1" colspan="1">17RCa</td><td rowspan="1" colspan="1">
<italic>ERBB2</italic>
</td><td rowspan="1" colspan="1">chr17:37871589</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Phe400Ser</td><td rowspan="1" colspan="1">c.1199T&#x0003e;C</td><td rowspan="1" colspan="1">2.7%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">27.1</td></tr><tr><td rowspan="1" colspan="1">18RCa</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">chr3:178919182</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">p.Glu223Lys</td><td rowspan="1" colspan="1">c.667G&#x0003e;A</td><td rowspan="1" colspan="1">2.94%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.834</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="1" colspan="1">18RCa</td><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">chr7:19156473</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">p.Phe158Leu</td><td rowspan="1" colspan="1">c.472T&#x0003e;C</td><td rowspan="1" colspan="1">3.77%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">32</td></tr><tr><td rowspan="1" colspan="1">18RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32907192</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Asp526Gly</td><td rowspan="1" colspan="1">c.1577A&#x0003e;G</td><td rowspan="1" colspan="1">2.88%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.354</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">11.21</td></tr><tr><td rowspan="1" colspan="1">18RCa</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30774446</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">p.Met47Thr</td><td rowspan="1" colspan="1">c.140T&#x0003e;C</td><td rowspan="1" colspan="1">7.02%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.774</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.7</td></tr><tr><td rowspan="1" colspan="1">25RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151879465</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">p.Lys1827Arg</td><td rowspan="1" colspan="1">c.5480A&#x0003e;G</td><td rowspan="1" colspan="1">4.4%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.868</td><td rowspan="1" colspan="1">24.3</td></tr><tr><td rowspan="1" colspan="1">26RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151873278</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">38</td><td rowspan="1" colspan="1">p.Ile3087Thr</td><td rowspan="1" colspan="1">c.9260T&#x0003e;C</td><td rowspan="1" colspan="1">3.41%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.985</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">29.8</td></tr><tr><td rowspan="1" colspan="1">26RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32906459</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.His282Asn</td><td rowspan="1" colspan="1">c.844C&#x0003e;A</td><td rowspan="1" colspan="1">4.17%</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.723</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">6.942</td></tr><tr><td rowspan="1" colspan="1">26RCa</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30774446</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">p.Met47Thr</td><td rowspan="1" colspan="1">c.140T&#x0003e;C</td><td rowspan="1" colspan="1">7.02%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.774</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.7</td></tr><tr><td rowspan="1" colspan="1">27RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32907224</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Glu537Gly</td><td rowspan="1" colspan="1">c.1610A&#x0003e;G</td><td rowspan="1" colspan="1">3.47%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.84</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">13.90</td></tr><tr><td rowspan="1" colspan="1">29RCa</td><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">chr7:19156511</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">p.Lys145Arg</td><td rowspan="1" colspan="1">c.434A&#x0003e;G</td><td rowspan="1" colspan="1">2.74%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.969</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">33</td></tr><tr><td rowspan="1" colspan="1">29RCa</td><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">chr7:19156527</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">p.Ser140Thr</td><td rowspan="1" colspan="1">c.418T&#x0003e;A</td><td rowspan="1" colspan="1">2.74%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">31</td></tr><tr><td rowspan="1" colspan="1">29RCa</td><td rowspan="1" colspan="1">
<italic>TWIST1</italic>
</td><td rowspan="1" colspan="1">chr7:19156545</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">p.Ile134Val</td><td rowspan="1" colspan="1">c.400A&#x0003e;G</td><td rowspan="1" colspan="1">2.67%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.542</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">30</td></tr><tr><td rowspan="1" colspan="1">31RCa</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">chr17:41245607</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Ser647Arg</td><td rowspan="1" colspan="1">c.1941T&#x0003e;A</td><td rowspan="1" colspan="1">3.64%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.991</td><td rowspan="1" colspan="1">0.891</td><td rowspan="1" colspan="1">22.4</td></tr><tr><td rowspan="1" colspan="1">33RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151879333</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">p.Ala1871Val</td><td rowspan="1" colspan="1">c.5612C&#x0003e;T</td><td rowspan="1" colspan="1">3.45%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.361</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">22.0</td></tr><tr><td rowspan="1" colspan="1">34RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614949</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Ile1131Thr</td><td rowspan="1" colspan="1">c.3392T&#x0003e;C</td><td rowspan="1" colspan="1">2.6%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.603</td><td rowspan="1" colspan="1">0.712</td><td rowspan="1" colspan="1">25.5</td></tr><tr><td rowspan="1" colspan="1">36RCa</td><td rowspan="1" colspan="1">
<italic>AKT1</italic>
</td><td rowspan="1" colspan="1">chr14:105236736</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">p.Asp462Gly</td><td rowspan="1" colspan="1">c.1385A&#x0003e;G</td><td rowspan="1" colspan="1">2.99%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.346</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">19.87</td></tr><tr><td rowspan="1" colspan="1">36RCa</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">chr17:41245353</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Glu732Gly</td><td rowspan="1" colspan="1">c.2195A&#x0003e;G</td><td rowspan="1" colspan="1">2.67%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.868</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">13.11</td></tr><tr><td rowspan="1" colspan="1">40RCa</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">chr3:178952118</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">p.Ile1058Thr</td><td rowspan="1" colspan="1">c.3173T&#x0003e;C</td><td rowspan="1" colspan="1">2.73%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.717</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">24.6</td></tr><tr><td rowspan="1" colspan="1">42RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151860736</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">43</td><td rowspan="1" colspan="1">p.Gln3309Arg</td><td rowspan="1" colspan="1">c.9926A&#x0003e;G</td><td rowspan="1" colspan="1">2.74%</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.671</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">14.94</td></tr><tr><td rowspan="1" colspan="1">42RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614925</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Ile1139Thr</td><td rowspan="1" colspan="1">c.3416T&#x0003e;C</td><td rowspan="1" colspan="1">2.53%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.946</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">25.1</td></tr><tr><td rowspan="1" colspan="1">42RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614931</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Ile1137Thr</td><td rowspan="1" colspan="1">c.3410T&#x0003e;C</td><td rowspan="1" colspan="1">3.8%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.994</td><td rowspan="1" colspan="1">25.9</td></tr><tr><td rowspan="1" colspan="1">43RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151833981</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">p.Glu4891Gly</td><td rowspan="1" colspan="1">c.14672A&#x0003e;G</td><td rowspan="1" colspan="1">2.7%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">32.0</td></tr><tr><td rowspan="1" colspan="1">43RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151833997</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">59</td><td rowspan="1" colspan="1">p.Tyr4886His</td><td rowspan="1" colspan="1">c.14656T&#x0003e;C</td><td rowspan="1" colspan="1">2.67%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">29.9</td></tr><tr><td rowspan="1" colspan="1">43RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151876970</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">37</td><td rowspan="1" colspan="1">p.Gly2464Glu</td><td rowspan="1" colspan="1">c.7391G&#x0003e;A</td><td rowspan="1" colspan="1">2.82%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">24.8</td></tr><tr><td rowspan="1" colspan="1">43RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32910755</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Ser755Pro</td><td rowspan="1" colspan="1">c.2263T&#x0003e;C</td><td rowspan="1" colspan="1">2.96%</td><td rowspan="1" colspan="1">0.03</td><td rowspan="1" colspan="1">0.469</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">11.00</td></tr><tr><td rowspan="1" colspan="1">43RCa</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30780523</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">p.Leu755Pro</td><td rowspan="1" colspan="1">c.2264T&#x0003e;C</td><td rowspan="1" colspan="1">2.52%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">29.6</td></tr><tr><td rowspan="1" colspan="1">46RCa</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32912838</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Phe1449Ser</td><td rowspan="1" colspan="1">c.4346T&#x0003e;C</td><td rowspan="1" colspan="1">2.56%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.861</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">22.7</td></tr><tr><td rowspan="1" colspan="1">46RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23619314</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">p.Leu1074Arg</td><td rowspan="1" colspan="1">c.3221T&#x0003e;G</td><td rowspan="1" colspan="1">4.11%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.986</td><td rowspan="1" colspan="1">27.1</td></tr><tr><td rowspan="1" colspan="1">46RCa</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23619329</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">p.Leu1069Arg</td><td rowspan="1" colspan="1">c.3206T&#x0003e;G</td><td rowspan="1" colspan="1">2.78%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.1</td></tr><tr><td rowspan="1" colspan="1">55RCa</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30776578</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">p.Gln283Arg</td><td rowspan="1" colspan="1">c.848A&#x0003e;G</td><td rowspan="1" colspan="1">4.84%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">24.0</td></tr><tr><td rowspan="1" colspan="1">TG23</td><td rowspan="1" colspan="1">
<italic>ERBB2</italic>
</td><td rowspan="1" colspan="1">chr17:37873643</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">p.Gly603Asp</td><td rowspan="1" colspan="1">c.1808G&#x0003e;A</td><td rowspan="1" colspan="1">2.7%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">28.9</td></tr><tr><td rowspan="1" colspan="1">TG30</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151849828</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">49</td><td rowspan="1" colspan="1">p.Leu4163Pro</td><td rowspan="1" colspan="1">c.12488T&#x0003e;C</td><td rowspan="1" colspan="1">3.85%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">24.6</td></tr><tr><td rowspan="1" colspan="1">TG30</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32911820</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Glu1110Lys</td><td rowspan="1" colspan="1">c.3328G&#x0003e;A</td><td rowspan="1" colspan="1">5.11%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">27.4</td></tr><tr><td rowspan="1" colspan="1">TG30</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23625332</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">p.Ser1065Phe</td><td rowspan="1" colspan="1">c.3194C&#x0003e;T</td><td rowspan="1" colspan="1">3.57%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">28.9</td></tr><tr><td rowspan="1" colspan="1">TG01</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32937375</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">p.Asp2679Gly</td><td rowspan="1" colspan="1">c.8036A&#x0003e;G</td><td rowspan="1" colspan="1">2.9%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.997</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.0</td></tr><tr><td rowspan="1" colspan="1">TG02</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">chr17:41245161</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Thr796Ile</td><td rowspan="1" colspan="1">c.2387C&#x0003e;T</td><td rowspan="1" colspan="1">15.76%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.707</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">15.36</td></tr><tr><td rowspan="1" colspan="1">TG04</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32971060</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">26</td><td rowspan="1" colspan="1">p.Ala3176Val</td><td rowspan="1" colspan="1">c.9527C&#x0003e;T</td><td rowspan="1" colspan="1">3.7%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.989</td><td rowspan="1" colspan="1">0.995</td><td rowspan="1" colspan="1">23.0</td></tr><tr><td rowspan="1" colspan="1">TG15</td><td rowspan="1" colspan="1">
<italic>BRCA2</italic>
</td><td rowspan="1" colspan="1">chr13:32906526</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Glu304Gly</td><td rowspan="1" colspan="1">c.911A&#x0003e;G</td><td rowspan="1" colspan="1">3.33%</td><td rowspan="1" colspan="1">0.05</td><td rowspan="1" colspan="1">0.996</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">22.9</td></tr><tr><td rowspan="1" colspan="1">TG19</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:152008963</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">p.Gln220Arg</td><td rowspan="1" colspan="1">c.659A&#x0003e;G</td><td rowspan="1" colspan="1">3.7%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.534</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">18.14</td></tr><tr><td rowspan="1" colspan="1">TG26</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614919</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Asp1141Gly</td><td rowspan="1" colspan="1">c.3422A&#x0003e;G</td><td rowspan="1" colspan="1">3.08%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.7</td></tr><tr><td rowspan="1" colspan="1">TG26</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">chr17:41243655</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Ser1298Pro</td><td rowspan="1" colspan="1">c.3892T&#x0003e;C</td><td rowspan="1" colspan="1">2.67%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.998</td><td rowspan="1" colspan="1">0.975</td><td rowspan="1" colspan="1">23.7</td></tr><tr><td rowspan="1" colspan="1">TG38</td><td rowspan="1" colspan="1">
<italic>AKT1</italic>
</td><td rowspan="1" colspan="1">chr14:105239701</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Leu282Val</td><td rowspan="1" colspan="1">c.844C&#x0003e;G</td><td rowspan="1" colspan="1">26.9%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.464</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">23.2</td></tr><tr><td rowspan="1" colspan="1">TG38</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30779233</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">p.Met483Thr</td><td rowspan="1" colspan="1">c.1448T&#x0003e;C</td><td rowspan="1" colspan="1">3.77%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">27.8</td></tr><tr><td rowspan="1" colspan="1">TG39</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">chr3:178938941</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">p.Gln728Arg</td><td rowspan="1" colspan="1">c.2183A&#x0003e;G</td><td rowspan="1" colspan="1">3.31</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.985</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">23.6</td></tr><tr><td rowspan="1" colspan="1">TG40</td><td rowspan="1" colspan="1">
<italic>PALB2</italic>
</td><td rowspan="1" colspan="1">chr16:23614982</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">p.Glu1120Gly</td><td rowspan="1" colspan="1">c.3359A&#x0003e;G</td><td rowspan="1" colspan="1">3.66%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.8</td></tr><tr><td rowspan="1" colspan="1">TG40</td><td rowspan="1" colspan="1">
<italic>RNF40</italic>
</td><td rowspan="1" colspan="1">chr16:30774446</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">p.Met47Thr</td><td rowspan="1" colspan="1">c.140T&#x0003e;C</td><td rowspan="1" colspan="1">7.02%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.774</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">25.7</td></tr><tr><td rowspan="1" colspan="1">TG52</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151949652</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.Leu483Pro</td><td rowspan="1" colspan="1">c.1448T&#x0003e;C</td><td rowspan="1" colspan="1">2.94%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">27.0</td></tr><tr><td rowspan="1" colspan="1">60RCa</td><td rowspan="1" colspan="1">
<italic>PIK3CA</italic>
</td><td rowspan="1" colspan="1">chr3:178928058</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">p.Trp446Arg</td><td rowspan="1" colspan="1">c.1336T&#x0003e;A</td><td rowspan="1" colspan="1">3.17%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">28.2</td></tr><tr><td rowspan="1" colspan="1">60RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151845181</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">p.Phe4611Leu</td><td rowspan="1" colspan="1">c.13831T&#x0003e;C</td><td rowspan="1" colspan="1">3.09%</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">23.7</td></tr><tr><td rowspan="1" colspan="1">60RCa</td><td rowspan="1" colspan="1">
<italic>KMT2C</italic>
</td><td rowspan="1" colspan="1">chr7:151845729</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">52</td><td rowspan="1" colspan="1">p.Val4428Ala</td><td rowspan="1" colspan="1">c.13283T&#x0003e;C</td><td rowspan="1" colspan="1">2.55%</td><td rowspan="1" colspan="1">0.01</td><td rowspan="1" colspan="1">0.944</td><td rowspan="1" colspan="1">0.999</td><td rowspan="1" colspan="1">26.6</td></tr><tr><td rowspan="1" colspan="1">60RCa</td><td rowspan="1" colspan="1">
<italic>BRCA1</italic>
</td><td rowspan="1" colspan="1">chr17:41244886</td><td rowspan="1" colspan="1">Missense_Mutation</td><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">p.His888Tyr</td><td rowspan="1" colspan="1">c.2662C&#x0003e;T</td><td rowspan="1" colspan="1">3.13%</td><td rowspan="1" colspan="1">0.02</td><td rowspan="1" colspan="1">0.767</td><td rowspan="1" colspan="1">poly</td><td rowspan="1" colspan="1">12.67</td></tr></tbody></table><table-wrap-foot><fn><p>Note: Here, 49 variants had potential pathogenic effects on protein functions and structures across 52 patients. poly: polymorphism</p></fn></table-wrap-foot></table-wrap></floats-group></article>